1、Please introduce us your main products and service of Yantai Jarmore Biotech Co., Ltd., and also your strength and you weakness against the target market. Yantai Jiamu Biotechnology Co., Ltd. focuses on preservation of stem cell biology sources in Shandong Province and provides stem cell production for clinical experiment. The company would also provide research on clinical core technology on the base of stem cell aiming at various diseases, gain admission of stem cell cure method and as for a further form first type of new drug.

2、Could you share with us your mind of setting up the company? Since you have built up a company in the states, what is the biggest difference of building up companies between China and the states in your opinion?　
To startup entrepreneur is the best way to transform technology into capacity. One would not only have sense of belonging and get national policy support, but also bring in advanced technology abroad to China and realize industrialization to present commercial value and personnel value.

3、As the first enterprise joining the BIOasis, what is the most point attracted you when you located the enterprise in Yantai Shandong and in the BIOasis?
 　Yantai is my home town. Shandong International Biotechnology Park is built in collaboration by Management Committee of Yantai High-Tech Zone and Shandong Luye Pharma Group Ltd. The park would get national policy support with high effect of demutualization operation. The excellent environment is suitable for living and work which is the dreaming place for entrepreneur.

4、How far is it for the stem cell technology benefitting the human being?
　Stem cell has differentiating potential of diversify possibility and had enormous clinical potential on curing rare illnesses. At present, stem cell had clinical value in some extent and had few effect of clinical experiment. If making great breakthrough on technology, stem cell would enter clinical application in large scale.

5、What is your opinion on the current hot wave of stem cell research in China?
　Stem cell is a new field in Bio-Pharma and the research level has tiny difference with that of developed country compared to traditional bio-pharma research. Due to ethics problem, research on stem cell lagged behind in certain period in America. Due to these reasons, stem cell is regarded as one of key directions of bio-pharma in China at present. If stem cell curing indication would not achieve breakthrough in short period, the upsurge would be in risk.